High-throughput screening (HTS) for potential anticancer agents requires a broad portfolio of assay platforms that may include kinase enzyme assays, protein-protein binding assays, and functional cell-based apoptosis assays. The authors have explored the use of fluorometric microvolume assay technology (the FMAT™ 8100 HTS System) in three distinct homogeneous HTS assays: (1) a Src tyrosine kinase enzyme assay, (2) a Grb2-SH2 protein-peptide interaction assay, and (3) an annexin V binding apoptosis assay. Data obtained from all three assays suggest that the FMAT system should facilitate the implementation of homogeneous assays for a wide variety of molecular targeted and cell-based screens. (Journal of Biomolecular Screening 2003:81-88) 
INTRODUCTION
A LTHOUGH SIGNIFICANT PROGRESS has been made in understanding the molecular mechanisms and pathophysiology of cancer, this disease remains one of the leading causes of death in the United States. The efficacy of many chemotherapeutic agents currently in use has been limited by concomitant toxicities. Treatments with improved antitumor efficacy and reduced toxicity are being actively sought in the areas of signal transduction, cell cycle regulation, apoptosis, telomere biology, and angiogenesis. 1, 2 In light of the numerous and diverse targets in oncology drug discovery, a wide array of high-throughput screening (HTS) assay technologies have been used, including enzyme-linked immunosorbent assays (ELISA), dissociation-enhanced lanthanide fluoroimmuno assays (DELFIA), scintillation proximity assays (SPA), fluorescence resonance energy transfer (FRET), fluorescence polarization (FP), and fluorometric imaging plate reader (FLIPR). Herein we describe the application of a new HTS technology, fluorometric microvolume assay technology (the FMAT™ 8100 HTS System), 3 to a tyrosine kinase assay, a proteinpeptide interaction assay, and a cellular assay for apoptosis.
The FMAT system uses a 633-nm helium-neon red laser as an excitation source, and the instrument contains 2 photomultiplier tubes to enable simultaneous detection of 2 independent red dye emissions. The FMAT instrument can scan 96-and 384-well microplates and is interfaced with the Zymark Twister™ to allow for unattended operation. Integrated image analysis software processes the images and generates data output that enumerates the number of cells or beads detected at the bottom of the well and quantifies the intensity of the emissions.
Protein tyrosine kinases are central players in cellular signaling pathways and thus represent an attractive target class in oncology. Src kinase is a member of a family of cytoplasmic protein tyrosine kinases that play an important role in cell cycle control, cell adhesion and movement, cell proliferation, and differentiation in a variety of cells and tissues. 4 Overexpression of Src has been associated with cancers such as colon and breast. 5, 6 Therefore, specific inhibitors of Src kinase have potential as antioncogenic agents. Conventional kinase assays have involved the use of radioactive tracers or multiple wash and incubation steps. We used Src kinase as a model kinase to evaluate the utility of the FMAT system in simplifying assay design for this common target class.
Growth factor receptor bound protein 2 (Grb2) is an adapter protein that plays a central role in signaling by receptor tyrosine kinases. Grb2 recruits the guanine nucleotide exchange factor son of sevenless (Sos) to the cell membrane, where it can activate Ras and trigger the downstream kinase cascade leading to cell prolifer-ation. 7 Small molecules that bind to the SH2 domain of Grb2 would interrupt these cell-signaling pathways and represent attractive targets for drug therapy in oncology. A conventional ELISA was previously used to discover inhibitors of the Grb2-SH2 interaction. 8 However, this assay format required numerous incubation steps and washes. Here we present the development and validation of a homogeneous bead-based fluorescent-linked immunosorbent assay (FLISA 9 ) using the FMAT system.
Apoptosis, or programmed cell death, is initiated in response to various stresses such as irradiation or irreparable DNA damage. 10, 11 Some transformed cells overexpress antiapoptotic proteins that allow cells to circumvent the normal apoptosis program. Many targets in oncology drug discovery therefore aim to selectively restore apoptotic programs in cancer cells, and the detection and quantitation of apoptosis are critical in the profiling of potential anticancer compounds. One of the early events during apoptosis is the externalization of phosphatidylserine (PS) to the outer leaflet of the plasma membrane. 12, 13 In the presence of calcium ion, annexin V, a phospholipid binding protein, binds to PS with a high affinity. [14] [15] [16] The binding of fluorescent annexin V is an established method in flow cytometry to assess apoptosis. 17 Some of the drawbacks of flow cytometric apoptosis methods include the need to trypsinize adherent cells and limited throughput. The FMAT system allows quantitation of annexin V binding in a microplatebased homogeneous assay format. 3 Herein we describe the evaluation of this technology applied to the profiling of known chemotherapeutic agents, Novartis development compounds, and a screen of 3866 purified natural products.
MATERIALS AND METHODS

Src kinase assay
Streptavidin beads, 6 µM in diameter (Spherotech, Libertyville, IL), were coated with a biotinylated peptide substrate (EGPWLEEEEEAYGWMDF-amide) (Roche, Indianapolis, IN) at a concentration of 0.1% beads and 250 nM biotinylated peptide in phosphate-buffered saline (PBS). The mixture was incubated at 4°C overnight with gentle rocking, and coated beads were subsequently pelleted and resuspended in PBS. Test compound, pp60 c-Src kinase (kindly provided by Dr. Doriano Fabbro, Novartis Oncology, Basel, Switzerland), 18 phosphotyrosine antibody (PY20-BD PharMingen, San Diego, CA), and Cy5-linked goat antimouse antibody (Amersham Pharmacia Biotech, Piscataway, NJ) were mixed in 96-well microplates (Applied Biosystems, Foster City, CA). The final concentrations in the reaction mixture were 0.00077% beads, 2 nM biotinylated substrate, 25 ng/ml c-Src kinase, 15 ng/ml antiphosphotyrosine antibody, and 0.3 µg/ml Cy5-conjugated goat antimouse antibody, diluted in assay buffer (50 mM Tris, pH 7.6, 10 mM MgCl 2 , 0.1 mM adenosine triphosphate [ATP], and 0.5% bovine serum albumin [BSA]). The reaction proceeded for 2 h at room temperature, and then ethylenediaminetetraacetic acid (EDTA) was added to stop the re-action. The plates were incubated for 4 h or overnight for the beads to settle and stacked in the robotic sample transporter (Twister™, Zymark, Hopkinton, MA) and read in the FMAT 8100 instrument. Staurosporine (Sigma, St. Louis, MO), a known inhibitor of protein tyrosine kinases, was tested to validate the assay.
Grb2-SH2 assay
Streptavidin beads, 4 µM in diameter (Spherotech, Libertyville, IL), were coated with biotinylated SH2 peptide (KPFY*VNEF) 8 at a concentration of 0.1% beads and 33 nM biotinylated peptide diluted in PBS. The mixture was incubated at 4°C overnight with gentle rocking, and the coated beads were then pelleted and resuspended in PBS. Test compounds, SH2-streptavidin beads, GST-Grb2, 8 and Cy5-conjugated anti-GST (Amersham Pharmacia Biotech, Piscataway, NJ, labeled according to manufacturer's instructions), diluted in assay buffer (5% BSA, 50 mM Tris, pH 8, 150 mM NaCl, 0.1% Tween 20), were mixed in 96-well microplates (Applied Biosystems, Foster City, CA). The final concentrations in the mixture were 0.5 nM bio-SH2, 0.0016% streptavidin beads, 4 nM GST-Grb2, and 1 µg/ml Cy5-anti-GST. Plates were incubated at room temperature for 4 h, stacked in the robotic sample transporter (Twister™, Zymark, Hopkinton, MA), and read in the FMAT 8100 instrument. Cyclic phosphopeptide inhibitors discovered in the conventional ELISA 8 were tested to validate the FMAT assay.
Annexin V apoptosis assay
Human colorectal carcinoma cells (HCT116) were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and maintained in RPMI1640 supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Annexin V (Sigma, St. Louis, MO) was labeled with Cy5.5 according to the manufacturer's instructions (Amersham Pharmacia Biotech, Piscataway, NJ). A cell-permeable, red nucleic acid-binding dye (similar to CentriRed™ Stain, Applied Biosystems, Foster City, CA) was used as a counterstain to enumerate the cells in the scanned area.
HCT116 cells were trypsinized, washed, counted, and plated in 96-well black microplates (Applied Biosystems, Foster City, CA) at a concentration of 10,000 cells per well. On the morning following plating, cells were treated with compounds with a final DMSO concentration not exceeding 0.5%. Cells were incubated at 37°C and 5% CO 2 in a humidified incubator for 24 h. Following incubation, 50 µl of a 5× calcium buffer containing 0.3 ng/ml Cy5.5annexin V and 30 nM nucleic acid stain were added to the cells. After a 1-h incubation, the plates were stacked in the robotic sample transporter (Twister™, Zymark, Hopkinton, MA) and read in the FMAT 8100 instrument.
To compare the apoptosis results with a standard 72-h cytotoxicity assay, several active compounds were tested in dose response using an MTS ([3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium, in-ner salt]) cytotoxicity kit (Promega Madison, WI). Data analysis was accomplished using customized Excel macros and templates.
RESULTS AND DISCUSSION
Src kinase assay
Protein tyrosine kinases are an important target class in anticancer therapy. For example, pharmacological inhibition of Bcr-Abl kinase has been shown to induce remissions in a number of chronic myelogenous leukemia patients. 19 We have developed a homogeneous, nonradioactive, bead-based assay to measure Src kinase activity ( Fig. 1) . A biotinylated substrate was tethered to a streptavidin-coated bead, and kinase activity was detected using a phosphotyrosine antibody and Cy5-conjugated antimouse antibody. The coefficient of variability (CV) of the positive controls on each plate averaged 8%. Staurosporine, a known inhibitor of protein kinases, was tested in the assay and inhibited c-Src kinase activity with an IC 50 of 38 nM (Fig. 2) , which was in the range stated in the literature. 20 This assay format can be easily adapted to measure the activity of a variety of kinases.
Grb2-SH2 assay
Disruption of protein-protein interactions is an anticancer strategy that has been employed to inhibit signal transduction pathways essential to tumor cells. A homogeneous, bead-based Grb2-SH2 protein-peptide assay was developed by tethering a biotinylated SH2 phosphopeptide to a streptavidin bead and detecting GST-Grb2 binding with Cy5-labeled anti-GST (Fig. 3) . The CV of the positive controls on each plate averaged 7%. Known cyclic phosphopeptide inhibitors of the Grb2-SH2 interaction 8 were tested in the assay. Figure 4 shows scanned images of fluorescent beads from wells containing no compound (A), 0.9 µM compound (B), and 25 µM compound (C), as well as the dose-response curve for compound 4 (D). 8 The IC 50 value from this experiment was 1.0 µM, which was comparable to the ELISA IC 50 value of 0.52 µM. Figure 5 compares the IC 50 values of 4 known inhibitors in the ELISA and the newly developed FLISA. The IC 50 values were similar, and the FLISA required just a single incubation and no wash steps.
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Annexin V apoptosis assay
One of the early markers of apoptosis is the translocation of PS to the outer leaflet of the cell membrane. 12, 13 The protein annexin V has a high affinity for PS and has been widely used as a reagent to measure apoptosis in applications such as fluorescence-activated cell sorting (FACS) analysis. [14] [15] [16] [17] Although FACS allows for extensive and detailed analysis of cells, it is not amenable to HTS. Cells must be detached from the well after treatment, and a large number of cells are required for the analysis. With the FMAT system, cells can be stained and evaluated in situ, resulting in a much higher throughput, low-manipulation assay format. Figure 6 illustrates image data generated from the FMAT 8100 system in the annexin V apoptosis assay. All wells were treated with 2 reagents, Cy5.5-labeled annexin V and nucleic acid stain. There was not a great deal of annexin V bound to healthy cells (untreated), so the majority of the staining observed was the nucleic acid stain alone (A). As the concentration of staurosporine increased in the medium, the percentage of cells that bound annexin V increased dramatically (B, C). By evaluating the percentage of apoptotic cells versus the total number of cells interrogated in the scan area, the apoptotic index (percentage of apoptotic cells in the well) for each well was determined, and a dose-response curve was generated. Staurosporine induced a maximum apoptotic index of 70% with an IC 50 of 25 nM (D), which is consistent with the data generated by flow cytometry.
The annexin V apoptosis assay was tested in a screen with 3866 pure natural products. Figure 7 shows an example of the apoptotic indices produced from a screening plate. Compounds were tested at a final concentration of 2.5 µM, and staurosporine (150 nM) and DMSO vehicle were included in quadruplicate as the positive and negative controls, respectively. The intra-assay CV of the staurosporine controls averaged 12% ± 5% (mean ± standard deviation, n = 62 plates), whereas the interassay CV was 17% for the staurosporine controls (apoptotic index = 67% ± 11%). Among the compounds screened, 1.3% of the compounds yielded apoptotic indices 4 standard deviations above the mean. A number of clinically useful anticancer agents, including doxorubicin and taxol, were tested and induced apoptosis in a dose-dependent fashion in the assay (Fig. 8) .
To compare the data from the apoptosis assay to that of a simple MTS viability assay, a series of compounds identified as apoptotic inducers in the FMAT screen were further characterized in an MTS viability assay. The IC 50 values derived from the 2 distinct assays correlated well among 6 of the 8 compounds studied (Table 1) . However, compounds 4, 8, and 9 deviated from this correlation. Compound 4 exhibited an IC 50 in the MTS assay that was 40-fold lower than in the apoptosis assay, suggesting that the cells were dying by a mechanism other than apoptosis. Compounds 8 and 9, by contrast, exhibited IC 50 values in the MTS assay that were at least 15-fold higher than in the apoptosis assay, suggesting that at the IC 50 values of the apoptosis assay, the compounds had not yet induced cell death but that many of the cells were undergoing early apoptosis, or the cells were alive with PS exposed on the outer layer of the cell membrane. The profiles of compounds 8 and 9, there-fore, are clearly distinct from that of compound 4. Taken together, these data suggest that the FMAT apoptosis assay may be used to distinguish effects of compounds that cannot be ascertained in a simple viability assay and may help guide decisions about which compounds to pursue in secondary assays.
CONCLUSION
The growing number of potential therapeutic targets in oncology drug discovery requires leveraging the best available screening technologies for HTS. Detection technologies such as FP, FLIPR, SPA, FRET, and DELFIA have collectively shown utility for a variety of target classes, including protein-protein interactions, Gprotein-coupled receptors (GPCRs), and other ligand-receptor interactions, proteases, and kinases. The FMAT system represents a new entry into the HTS arena that we and others have demonstrated to be suitable for a wider array of both molecular-targeted and cell-based assay platforms than other single-detection technologies. FMAT applications described to date include immunoassays 9 and GPCRs, 3, [21] [22] [23] in addition to the protein-protein interaction, kinase assay, and the apoptosis assay described here ( Table 2) . Scanning laser imaging is likely to be a widely exploited technology in the near future in HTS, and one could envision expanding 
